P16在乳腺癌及乳腺腺病中的表达及其临床意义(2)
 |
| 第1页 |
参见附件(1556KB，2页)。
[参考文献]
[1] Kamb A,Gruis NA,Weaver-Feldhaus J,et al. A cell cycle regulator potentially involvedin genesis of many tumor types[J]. Science,1994,264(5157):436-440.
[2] Nobori T,Miura K,Wu DJ,et al. Deletion of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers[J]. Nature,1994,368(6473):753-756.
[3] Okamoto A,Demetrick DJ,Spillare EA,et al. Mutationand altered expression of p16 in human cancer[J]. Proc Nad Acad Science USA,1994,91(23):11045-11049.
[4] Liu WH,Kaur M,Wang G,et al. Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cell and turmors[J]. Cancer Res,2004,64:2544-2551.
[5] Lee TL,Leung WK,Chan MW,et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma[J]. Clin Cancer Res,2002,8(6):1761-1766.
[6] Bian YS,Osterheld MC,Fontolliet C,et al. p16 inactivation by methylation of the CDKN2A promoter Occurs early during neoplastic progression in Barretfs esophagus[J]. Gastroentero1ogy,2002,22(4):1113-1121.
[7] Kamb A,Liu QY,Harshman K,et al. Rates of P16(MTS1)mutation in primary tumors with 9p lose[J]. Science,1994,265(16):425.
(收稿日期:2009-12-16)
您现在查看是摘要介绍页，详见PDF附件(1556KB，2页)。